US 12,305,171 B2
Compositions and methods for treating cancer
David J. Elzi, San Antonio, TX (US); William E. Bauta, San Antonio, TX (US); and Vivienne I. Rebel, San Antonio, TX (US)
Assigned to bioAffinity Technologies, Inc., San Antonio, TX (US)
Filed by bioAffinity Technologies, Inc., San Antonio, TX (US)
Filed on Jun. 28, 2021, as Appl. No. 17/359,905.
Application 17/359,905 is a continuation in part of application No. PCT/US2019/068423, filed on Dec. 23, 2019.
Claims priority of provisional application 63/044,771, filed on Jun. 26, 2020.
Claims priority of provisional application 62/785,592, filed on Dec. 27, 2018.
Prior Publication US 2023/0035774 A1, Feb. 2, 2023
Int. Cl. C12N 15/113 (2010.01); C12Q 1/68 (2018.01)
CPC C12N 15/1138 (2013.01) [C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2320/30 (2013.01)] 15 Claims
 
1. A double stranded RNA interference (RNAi) agent comprising:
a combination of (i) a first double-stranded ribonucleic acid (dsRNA) for inhibiting expression of a CD320 gene wherein the first dsRNA comprises a sense strand and an antisense strand forming a duplex, and (ii) a second dsRNA for inhibiting expression of a LRP2 gene wherein the second dsRNA comprises a sense strand and an antisense strand forming a duplex, and wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA wherein the antisense strand of (i) the first dsRNA is selected from SEQ ID NO:1-93 and the antisense strand of (ii) the second dsRNA is selected from SEQ ID NO: 187-560.